Natrecor
Natrecor (nesiritide) is a sterile, purified recombinant human B-type natriuretic peptide (hBNP). It works by binding to the particulate guanylyl cyclase receptor of vascular smooth muscle and endothelial cells, leading to smooth muscle cell relaxation, vasodilation, and reduction in pulmonary capillary wedge pressure and systemic arterial pressure.
Dosage by Body Weight
Strictly for intravenous use in a hospital setting. The standard adult dose is an initial IV bolus of 2 mcg/kg, followed by a continuous IV infusion rate of 0.01 mcg/kg/min. Dosage should be calculated precisely based on body weight. Pediatric safety and effectiveness have not been established.
- Body Weight
- Below 5 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of Natrecor in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of Natrecor in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of Natrecor in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of Natrecor in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and effectiveness of Natrecor in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not established | Not recommended | Safety and effectiveness of Natrecor in pediatric patients have not been established. |
| 5-7 kg | Not established | Not recommended | Safety and effectiveness of Natrecor in pediatric patients have not been established. |
| 8-10 kg | Not established | Not recommended | Safety and effectiveness of Natrecor in pediatric patients have not been established. |
| 11-15 kg | Not established | Not recommended | Safety and effectiveness of Natrecor in pediatric patients have not been established. |
| 16-20 kg | Not established | Not recommended | Safety and effectiveness of Natrecor in pediatric patients have not been established. |
Formulation
Purpose
Used for the intravenous treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity.
Generic Name
NesiritideScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.